Inbrija is an anti-Parkinson's disease drug owned by Acorda. It was first authorized for market use on December 21, 2018. The active ingredient in Inbrija is levodopa, and it's available in a powder for inhalation dosage forms.
The generic versions of Inbrija may become available after November 16, 2032. This is the expiry date of the last patent held by Acorda for this drug.
Inbrija is primarily used as an intermittent treatment of off episodes in patients with Parkinson's disease who are being treated with a combination of carbidopa and levodopa. By inhalation, levodopa powder particles are delivered directly to the patient's system, providing relief from the symptoms of Parkinson's disease.
Inbrija's patent portfolio contains a total of 10 patents. Out of these, four have already expired. The remaining patents ensure Acorda's exclusivity on Inbrija till November 16, 2032. Hence, the earliest possible date for a Inbrija generic to become available is after this date. The patents that are crucial to the release of a Inbrija generic are: US8945612, US8685442, US9393210, and US8545878. Below are the details of the patent: